Rheumatoid arthritis (RA) patients refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol-Myers Squibb’s Orencia, Roche’s Actemra / RoActemra, Roche’s Rituxan / MabThera). The recent launch of AbbVie’s Rinvoq in the United States and Europe, along with Pfizer’s Xeljanz in Europe and Eli Lilly / Incyte’s Olumiant in both the United States and Europe, gives physicians more treatment options with a convenient route of administration (i.e., oral). The launch of an additional interleukin(IL)-6 inhibitor, Regeneron / Sanofi’s Kevzara, has further expanded the treatment armamentarium. Although the RA therapy market offers multiple efficacious and relatively safe agents, patients refractory to TNF-α inhibitors have limited options, even with the recent entry of newer agents; therefore, substantial unmet need remains in the treatment of tumor necrosis factor inhibitor (TNFi)-refractory RA.
Questions Answered:
Product Description:
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. rheumatologists and 30 European rheumatologists, fielded in January 2020
Key companies: Roche, Bristol-Myers Squibb, AbbVie, Pfizer, Eli Lilly, Incyte, Sanofi, Regeneron
Key drugs: Rituxan / MabThera, Orencia, Actemra / RoActemra, Xeljanz, Olumiant, Rinvoq